Compare Recursion Pharmaceuticals Inc (RXRX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while State Street Technology Select Sector SPDR ETF trades at $187.68. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLK | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $198.21 |
52-Week Low | $2.84 | $127.49 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
XLK trades at $187.87, up 0.3% today, with a bullish technical signal from moving averages and support at $185. The ETF holds a concentrated mega-cap tech strategy with a low 0.08% expense ratio, though key financial ratios are unavailable. Recent news highlights sector inflows and AI-driven software shifts.
Outlook is supported by tech sector momentum and AI adoption, but risks include high concentration in top holdings and valuation sensitivity. Analysts favor XLK for its cost efficiency and exposure to AI growth, yet investors face volatility from economic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
